{"product_id":"haemonetics-five-forces-analysis","title":"Haemonetics Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eHaemonetics faces moderate supplier power, intense rivalry among med‑tech peers, and evolving buyer dynamics as hospitals demand value-based solutions. Regulatory pressures and innovation-driven substitutes heighten strategic risk, while entry barriers stay significant. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Haemonetics’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers of sterile disposables, sensors and medical-grade polymers are highly concentrated, making sourcing tenuous for Haemonetics; qualification and validation often take months to over a year, raising switching costs. Single- or dual-source arrangements give vendors pricing and delivery leverage, and historical supply disruptions have caused multi-week production delays that can materially affect Haemonetics’ ~$1.2 billion revenue scale in 2024. Any vendor outage can therefore cascade into service shortfalls and revenue volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSterilization capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eETO and gamma sterilization slots remained tight in 2024 with industry utilization exceeding 85%, creating capacity bottlenecks that raise costs and extend lead times for Haemonetics; requalification for alternative providers typically takes 6–12 months, adding delay and expense. This concentrated supplier base and regulatory complexity materially increases supplier bargaining power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElectronics and software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEmbedded controllers, chips, and software modules face cyclicality in supply that can create lead-time volatility and sourcing risk; global semiconductor sales were roughly $561 billion in 2024, underscoring tight competition for components. Design changes trigger regulatory revalidation, raising dependence on qualified vendors and contract rigidity. Heightened cybersecurity and interoperability requirements narrow vendor pools, concentrating negotiating power and driving pricing and terms pressure on Haemonetics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw materials and reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAnticoagulants, filters and membranes require tight specifications and GMP oversight, narrowing qualified suppliers and raising switching costs; Haemonetics reported 2024 revenue of $1.29 billion, exposing margins to input cost volatility. Price swings or shortages in 2024 spare parts and reagents markets materially affected industry margins, and dual-sourcing is feasible but usually demands 6–12 months of validation and regulatory documentation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQualified suppliers constrained by GMP\u003c\/li\u003e\n\u003cli\u003e2024 Haemonetics revenue: $1.29 billion\u003c\/li\u003e\n\u003cli\u003eInput price\/shortage risk pressures margins\u003c\/li\u003e\n\u003cli\u003eDual-sourcing requires 6–12 months validation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHighly specialized contract manufacturers create strong switching frictions for Haemonetics; tech transfer and process validation typically require 6–18 months, favoring incumbents. Volume commitments and tooling lock‑ins further raise supplier leverage, and during high utilization (\u0026gt;85%) suppliers can extract price concessions and priority allocations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialization: long tech transfer (6–18 mo)\u003c\/li\u003e\n\u003cli\u003eValidation: favors incumbents\u003c\/li\u003e\n\u003cli\u003eLock‑ins: tooling\/volume commitments\u003c\/li\u003e\n\u003cli\u003eLeverage: pricing \u0026amp; priority during \u0026gt;85% utilization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated suppliers and long validation risk multi-week delays as ETO use exceeds \u003cstrong\u003e\u0026gt;85%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers of sterile disposables, sterilization and semiconductors are concentrated, raising switching costs and enabling pricing\/delivery leverage that can cause multi-week production delays and revenue volatility for Haemonetics (2024 revenue $1.29B). Validation\/tech transfer typically 6–18 months; ETO\/gamma capacity \u0026gt;85% utilization in 2024, tightening lead times and margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$1.29B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eETO\/gamma util.\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValidation time\u003c\/td\u003e\n\u003ctd\u003e6–18 mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eUncovers key competitive drivers—supplier and buyer power, substitutes, and entry barriers—affecting Haemonetics’ pricing, margins, and market position. Provides actionable insights on disruptive threats and strategic levers for investors and corporate strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA clear, one-sheet Porter's Five Forces analysis for Haemonetics that pinpoints supplier, buyer, competitive and regulatory pressures—easy to update with your data, ready to drop into decks to quickly resolve strategic uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustomer consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCustomer consolidation has strengthened bargaining power as large plasma collectors like CSL and Grifols and integrated hospital systems aggregate purchases, driving centralized tenders that amplify negotiation leverage.\u003c\/p\u003e\n\u003cp\u003eVolume-based discounts and contract tiers are often table stakes, forcing Haemonetics to offer deeper pricing or bundled service models to secure large accounts.\u003c\/p\u003e\n\u003cp\u003eVendors must tailor value propositions with dedicated account teams, outcomes-based pricing, and integration capabilities to remain competitive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGPO and tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOver 95% of US hospitals use GPOs and GPO-driven contracts capture over 80% of institutional purchasing, driving supplier discounts of roughly 5–20% and shaping pricing\/access in hospitals and blood centers.\u003c\/p\u003e\n\u003cp\u003eCompetitive bids compress margins and typically lock pricing and volume for 3–5 year terms, with compliance clauses enforcing service levels and uptime often at or above 99%.\u003c\/p\u003e\n\u003cp\u003eLosing a tender can translate into multi-year share and revenue losses equal to the contract duration and awarded volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwitching costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaemonetics large installed base and device footprint, combined with staff training and validated workflows, create high stickiness; the company reported roughly $1.0 billion in revenue in 2024, reflecting recurring service demand. Data integrations and hospital SOPs further deter rapid change, lengthening procurement cycles. Buyers still use switching threats to extract concessions, so published clinical outcomes and cost-per-patient data are critical to defend price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutcome focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCustomers demand lower cost per procedure and better clinical metrics; Medicare Hospital VBP in 2024 ties roughly 2% of payments to performance, pushing hospitals to use KPIs like throughput and readmission to negotiate; vendors must credibly quantify ROI and TCO and cite outcome data—published studies show blood‑management programs can cut transfusions up to 30%, which helps blunt pure price pressure.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCost focus: lower cost per procedure\u003c\/li\u003e\n\u003cli\u003eKPIs: pay‑for‑performance (~2% Medicare VBP) and throughput\u003c\/li\u003e\n\u003cli\u003eVendor proof: credible ROI\/TCO and outcome data (transfusion reductions up to 30%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService expectations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBuyers demand 24\/7 support, 99.9% uptime guarantees, and assured consumable availability—service SLAs become key negotiation levers in procurement.\u003c\/p\u003e\n\u003cp\u003eBundled service contracts can cap price pressure but increase Haemonetics obligations and liability exposure; SLA credit frameworks (commonly up to 10% of service fees) shape negotiations.\u003c\/p\u003e\n\u003cp\u003ePoor service rapidly opens doors for competitors given high clinical risk sensitivity and procurement turnover.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 support\u003c\/li\u003e\n\u003cli\u003e99.9% uptime\u003c\/li\u003e\n\u003cli\u003eConsumable availability\u003c\/li\u003e\n\u003cli\u003eSLA leverage (up to 10%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGPO consolidation (\u003cstrong\u003e\u0026gt;95%\u003c\/strong\u003e) and institutional buys (\u003cstrong\u003e\u0026gt;80%\u003c\/strong\u003e) drive \u003cstrong\u003e5–20%\u003c\/strong\u003e discounts, 3–5yr tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomer consolidation and GPO-driven contracts (\u0026gt;95% hospitals, \u0026gt;80% institutional purchasing) amplify buyer leverage, forcing volume discounts (5–20%) and 3–5 year tenders. Haemonetics' $1.0B 2024 revenue and high switching costs help defend pricing, but buyers extract concessions via SLAs (99.9% uptime) and outcome-linked KPIs (Medicare VBP ~2%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO penetration\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003ctd\u003eCentralized bargaining\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional purchasing\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80%\u003c\/td\u003e\n\u003ctd\u003ePrice compression\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical discounts\u003c\/td\u003e\n\u003ctd\u003e5–20%\u003c\/td\u003e\n\u003ctd\u003eMargin pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract term\u003c\/td\u003e\n\u003ctd\u003e3–5 yrs\u003c\/td\u003e\n\u003ctd\u003eMulti-year revenue risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHaemonetics rev\u003c\/td\u003e\n\u003ctd\u003e$1.0B (2024)\u003c\/td\u003e\n\u003ctd\u003eInstalled-base defense\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSLA uptime\u003c\/td\u003e\n\u003ctd\u003e99.9%\u003c\/td\u003e\n\u003ctd\u003eNegotiation lever\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare VBP\u003c\/td\u003e\n\u003ctd\u003e~2%\u003c\/td\u003e\n\u003ctd\u003eKPI-driven purchasing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eHaemonetics Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Haemonetics Porter’s Five Forces analysis you’ll receive—no mockups, no placeholders. The document is fully formatted, professionally written, and ready for immediate download upon purchase. It contains the complete competitive assessment and strategic insights as displayed here. What you see is the final deliverable available instantly after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56163004809593,"sku":"haemonetics-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/haemonetics-five-forces-analysis.png?v=1762712906","url":"https:\/\/portersfiveforce.com\/products\/haemonetics-five-forces-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}